Transcutaneous immunization with an outer membrane protein of <i>Porphyromonas gingivalis</i> without adjuvant elicits marked antibody responses

Koizumi, Yukiko; Kurita‐Ochiai, Tomoko; Yamamoto, Masafumi

doi:10.1111/j.1399-302x.2007.00400.x

Cited by 17 publications

(8 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies showed that a monoclonal antibody (MAb) to 40-kDa OMP inhibits coaggregation by P. gingivalis and promotes complement-mediated bactericidal and opsonic activity for the phagocytosis of P. gingivalis (1,21,46). Furthermore, rats that are transcutaneously immunized with a 40-kDa OMP vaccine have significantly diminished P. gingivalis-induced abscess formation (24). Therefore, the development of a mucosal 40-kDa OMP vaccine for humans may be a significant milestone in the search for an effective vaccine against P. gingivalis infection.…”

Section: Discussionmentioning

confidence: 99%

Nasal Immunization with Porphyromonas gingivalis Outer Membrane Protein Decreases P. gingivalis -Induced Atherosclerosis and Inflammation in Spontaneously Hyperlipidemic Mice

Koizumi¹,

Kurita‐Ochiai²,

Oguchi

et al. 2008

Infect Immun

Self Cite

View full text Add to dashboard Cite

Porphyromonas gingivalis has been shown to accelerate atherosclerotic lesion development in hyperlipidemic animals. We assessed the potential of a nasal vaccine against P. gingivalis infection for the prevention of atherosclerosis. Apolipoprotein E-deficient spontaneously hyperlipidemic (Apoe shl ) mice were nasally immunized with the 40-kDa outer membrane protein (OMP) of P. gingivalis plus cholera toxin (CT) as adjuvant and then challenged intravenously with P. gingivalis strain 381. The animals were euthanized 11 or 14 weeks later. Atheromatous lesions in the proximal aorta of each animal were analyzed histomorphometrically, and the serum concentrations of 40-kDa OMP-specific antibodies and cytokines were determined. The areas of the aortic sinus that were covered with atherosclerotic plaque and the serum levels of inflammatory cytokines and chemokines were increased in Apoe shl mice challenged with P. gingivalis compared to nonchallenged mice. In comparison, nasal immunization with 40-kDa OMP plus CT significantly reduced atherosclerotic plaque accumulation in the aortic sinus and lowered the serum levels of cytokines and chemokines compared to nonimmunized animals. Nasal immunization also induced 40-kDa OMP-specific serum immunoglobulin G (IgG) and saliva IgA antibody responses. These findings suggest that systemic infection with P. gingivalis accelerates atherosclerosis in Apoe shl mice, and 40-kDa OMP plus CT may be an effective nasal vaccine for the reduction of atherosclerosis accelerated by P. gingivalis in the hyperlipidemic mouse model.

show abstract

Section: Discussionmentioning

confidence: 99%

Nasal Immunization with Porphyromonas gingivalis Outer Membrane Protein Decreases P. gingivalis -Induced Atherosclerosis and Inflammation in Spontaneously Hyperlipidemic Mice

Koizumi¹,

Kurita‐Ochiai²,

Oguchi

et al. 2008

Infect Immun

Self Cite

View full text Add to dashboard Cite

show abstract

“…(13,14) Furthermore, nasal or transcutaneous immunization with 40k-OMP prevented alveolar bone loss or abdominal abscess formation in response to a P. gingivalis challenge. (15,16) Therefore, the use of 40k-OMP as a mucosal vaccine antigen may be beneficial in the development of a periodontal vaccine and for the preventive therapy of cardiovascular disease (CVD).…”

Section: Introductionmentioning

confidence: 99%

Intranasal immunization withPorphyromonas gingivalisand atherosclerosis

Koizumi

Kurita‐Ochiai

Oguchi

et al. 2009

Immunopharmacology and Immunotoxicology

View full text Add to dashboard Cite

Periodontal disease is a highly prevalent disorder affecting up to 90% of the global population. Recent epidemiological studies have shown that an association exists between periodontal disease and cardiovascular disease. Porphyromonas gingivalis, the causative agent of destructive chronic inflammation in the periodontium, can accelerate atheroma deposition in animal models. Emerging evidence suggests that vaccination against this pathogen's virulence factors may confer disease resistance. In this review, we focus on the role of inflammatory mechanisms in the formation and activation of atherosclerotic plaques accelerated by P. gingivalis in an apo E-deficient mouse model. Further, we examine whether a nasal vaccine-induced antigen-specific mucosal response can reduce P. gingivalis-accelerated atherosclerosis.

show abstract

“…Rat Induced serum IgG, IgA and IgG in saliva. Protection against challenge with P. gingivalis 381 [84] 40-kDa OMP with mCTA/LTB in. Mouse Induced high levels of 40-kDa-specific serum IgG, IgA and IgA in saliva.…”

Section: Immunization With P Gingivalis-specific Antigensmentioning

confidence: 99%

“…Second, transcutaneous or nasal immunization of mice with 40-kDa OMP and CT has shown to induce serum IgG, IgA and IgG in saliva [82,83]. Presently, adjuvant-free transcutaneous immunization of rats with 40-kDa OMP induced a similar immune response and protection against subcutaneous challenge with P. gingivalis 381, a nonvirulent strain [84]. To circumvent the adverse effects of the CT, a nontoxic chimeric variant of CT could be used.…”

Section: Immunization With Ompsmentioning

confidence: 99%

Feasibility and therapeutic strategies of vaccines againstPorphyromonas gingivalis

Jong¹,

Reijden²

2010

Expert Review of Vaccines

View full text Add to dashboard Cite

Periodontitis is a chronic infectious disease that is highly prevalent worldwide and is characterized by inflammation of the gums, and loss of connective tissue and bone support. The Gramnegative anerobic bacterium Porphyromonas gingivalis is generally accepted as the main etiological agent for chronic periodontitis. The objective of this paper is to elucidate the feasibility of achieving protection against periodontitis though immunization against P. gingivalis. Until now, animal studies have showed no complete protection against P. gingivalis. However, current knowledge about P. gingivalis structures could be applicable for further research to develop a successful licensed vaccine and alternative therapeutic strategies. This review reveals that a multicomponent vaccine against P. gingivalis, which includes structures shared among P. gingivalis serotypes, will be feasible to induce broad and complete protection. Keywords: capsule • fimbriae • gingipain • immunization • periodontitis • Porphyromonas gingivalis • vaccineFeasibility and therapeutic strategies of vaccines against Porphyromonas gingivalis Expert Rev. Vaccines 9(2), 193-208 (2010) For reprint orders, please contact reprints@expert-reviews.com Expert Rev. Vaccines 9(2), (2010)

show abstract

Transcutaneous immunization with an outer membrane protein of Porphyromonas gingivalis without adjuvant elicits marked antibody responses

Abstract: Since 40k-OMP-specific IgG inhibited the coaggregation of P. gingivalis with Streptococcus gordonii, and the hemagglutinin activity of P. gingivalis, TCI with the 40k-OMP may be important as an adjuvant-free immunogen for the prevention of chronic periodontitis.

Cited by 17 publications

References 49 publications

Nasal Immunization with Porphyromonas gingivalis Outer Membrane Protein Decreases P. gingivalis -Induced Atherosclerosis and Inflammation in Spontaneously Hyperlipidemic Mice

Nasal Immunization with Porphyromonas gingivalis Outer Membrane Protein Decreases P. gingivalis -Induced Atherosclerosis and Inflammation in Spontaneously Hyperlipidemic Mice

Intranasal immunization withPorphyromonas gingivalisand atherosclerosis

Feasibility and therapeutic strategies of vaccines againstPorphyromonas gingivalis

Contact Info

Product

Resources

About